» Articles » PMID: 3259600

Protective, Restorative, and Therapeutic Properties of Recombinant Human IL-1 in Rodent Models

Overview
Journal J Immunol
Date 1988 Jun 1
PMID 3259600
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Human rIL-1 alpha and -1 beta are shown to increase significantly the CFU-culture activity in the spleen as well as at other sites after i.v. or i.p. administration. IL-1 can also significantly increase survival and can "rescue" a number of animals if administered either before or after lethal doses of cyclophosphamide or gamma-irradiation. The protective and reconstitutive activities of the rIL-1 are shown to correlate with increased CFU-culture frequency and total number, as well as increased cellularity in the bone marrow and peripheral blood, suggesting that this is one of their mechanisms of action. The sequence and timing of administration of human rIL-1 is critical for the protection or rescue of animals receiving DNA-damaging agents; maximal activity is achieved when IL-1 is given 20 h before insult or 48 h after alkylating agent administration. Minimal therapeutic activity is observed with IL-1 as a single agent for the treatment of metastatic disease compared with other biologic response modifiers including IFN-gamma.

Citing Articles

Unlocking the 'ova'-coming power: immunotherapy's role in shaping the future of ovarian cancer treatment.

Haines N, Fowler M, Zeh B, Kriete C, Bai Q, Wakefield M Med Oncol. 2024; 41(3):67.

PMID: 38286890 DOI: 10.1007/s12032-023-02281-6.


Report of a phase I evaluation of dose and schedule of interleukin-1 alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group study (PX990) and review of IL-1-based studies of hematopoietic reconstitution.

Dutcher J, Neuberg D, Atkins M, Tester W, Wadler S, Stewart J J Interferon Cytokine Res. 2014; 34(5):376-84.

PMID: 24433038 PMC: 4015471. DOI: 10.1089/jir.2013.0010.


Recombinant transforming growth factor beta 1 and beta 2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin.

Grzegorzewski K, Ruscetti F, Usui N, Damia G, Longo D, Carlino J J Exp Med. 1994; 180(3):1047-57.

PMID: 8064224 PMC: 2191629. DOI: 10.1084/jem.180.3.1047.


Exogenous tumor necrosis factor alpha and interleukin-1 alpha increase resistance to Salmonella typhimurium: efficacy is influenced by the Ity and Lps loci.

Morrissey P, Charrier K, Vogel S Infect Immun. 1995; 63(8):3196-8.

PMID: 7622247 PMC: 173436. DOI: 10.1128/iai.63.8.3196-3198.1995.


Interleukins. Clinical pharmacology and therapeutic use.

Aulitzky W, Schuler M, Peschel C, Huber C Drugs. 1994; 48(5):667-77.

PMID: 7530625 DOI: 10.2165/00003495-199448050-00002.